RxDoctor Payments Data

Tahmeed Contractor, MD

Clinical Cardiac Electrophysiology · Madison, WINPI 1073778726

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (35.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medical Device Business Services, Inc. at 35.3% of the total. Reporting peaked in 2024 at $10,887 and has fallen 95.5% since, to $488 in 2025.

$24,191in general payments, 2019–2025

Across 248 payments — averaging $97.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$9K
  • Medtronic$8K
  • Abbott$3K
  • Biosense Webster, Inc.$2K
  • Boston Scientific$1K
  • Philips North America LLC$842
  • plus $744 from 15 others

What the payments were for

  • Consulting fees$8,55035%
  • Speaking & faculty fees$5,55023%
  • Travel & lodging$3,79616%
  • Food & beverage$6,23326%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,191 in reported general payments places this provider in the 70th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

See all clinical cardiac electrophysiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$331,178
Medicare patients
586
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$250,078
XareltoRivaroxaban53$78,531
MultaqDronedarone Hcl13$27,242
SotalolSotalol Hcl57$1,818
Amiodarone Hcl81$1,394
Metoprolol Succinate116$1,355
Mexiletine Hcl12$1,319
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$870
Flecainide Acetate25$628
Carvedilol51$353
Warfarin Sodium28$271
Metoprolol Tartrate45$253
Sucralfate27$240
Pantoprazole Sodium29$133
ClopidogrelClopidogrel Bisulfate12$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$250,078206 claims
Sanofi-aventis U.S. LLCMultaq$28$27,24213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

Other clinical cardiac electrophysiology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →